MVA-BN疫苗真实世界安全性数据:皮内接种免疫预防猴痘后晕厥频率增加
该研究检索巴伐利亚北欧公司的全球安全性数据库,比较MVA-BN疫苗不同接种途径的不良事件报告。共报告9585例不良事件,心肌炎或心包炎发生率低于每10万剂1例;结论认为皮下接种安全性与已知一致,皮内接种可能增加晕厥事件频率。
要点
- MVA-BN疫苗全球安全性数据库共报告9585例不良事件。
- 心肌炎或心包炎发生率低于每10万剂1例。
核心结论
- 大规模接种的真实世界数据证实MVA-BN疫苗皮下接种的安全性特征与已知一致。
- 皮内接种可能增加晕厥事件的发生频率。
研究设计与样本
- 检索巴伐利亚北欧公司全球安全性数据库,收集MVA-BN疫苗所有免疫接种后不良事件(AEFI)。
- 比较不同接种途径的AEFI数量,并绘制猴痘疫情期间选定事件与接种剂次的时间趋势图。
主要发现
- 共报告9585例AEFI。
- 心肌炎或心包炎发生率为每10万剂低于1例。
- 报告晕厥、昏厥或意识丧失89例;2022年8月美国皮内接种紧急使用授权后该数量上升。
关键数值与推荐
- 心肌炎或心包炎发生率:每10万剂低于1例。
- 晕厥、昏厥或意识丧失报告例数:89例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MVA-BN vaccine (Jynneos, Imvamune, Imvanex) was used widely in the 2022 mpox outbreak. This experience provides real-world evidence about the vaccine's safety, particularly regarding intradermal use. METHODS: Bavarian Nordic's global safety database was searched for all adverse events following immunization (AEFIs) with MVA-BN. AEFI numbers were compared among administration routes. Selected events and administered doses were graphed over the mpox outbreak period. RESULTS: A total of 9585 AEFIs have been reported. The rate of myocarditis or pericarditis was <1 per 100,000 doses administered. Eighty-nine cases of syncope, fainting, or loss of consciousness were reported. This number rose after the August 2022 US emergency use authorization for intradermal administration, as did the proportion of all syncope AEFIs reported following intradermal administration (78,7 %). CONCLUSION: Real-world data from large-scale administration of MVA-BN has confirmed the vaccine's established safety profile when administered subcutaneously. Intradermal administration is likely associated with increased syncopal event frequency.
引用
- Weidenthaler H, Vidojkovic S, Martin BK, et al. Real-world safety data for MVA-BN: Increased frequency of syncope following intradermal administration for immunization against mpox disease. Vaccine. 2024. PMID: 38839518. doi:10.1016/j.vaccine.2024.05.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。